Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases:Two case reports  

作　　者：Jun-Hui Guo Yuan-Yuan Wang Jiang-Wei Zhang Pei-Min Liu Yan-Jun Hao Hai-Rui Duan 

机构地区：[1]Department of Oncology,The Second Affiliated Hospital of Henan University of Chinese Medicine,Henan Province Hospital of TCM,Zhengzhou 450002,Henan Province,China

出　　处：《World Journal of Clinical Cases》2020年第7期1326-1336,共11页世界临床病例杂志

基　　金：National Natural Science Foundation of China,No.81872032.

摘　　要：BACKGROUND Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor.Apatinib has demonstrated encouraging antitumor activities.This study aimed to observe the efficacy and safety of apatinib for the treatment of multiple brain micrometastases.CASE SUMMARY We report two patients with multiple brain micrometastases after failure of second-line treatment.Both patients had extracerebral metastases.When the patients took 250 mg/d apatinib orally,the intracerebral lesions disappeared.The extracerebral lesions were partially alleviated.Both patients had a progressionfree survival of more than 12 mo and were still stable.The safety was good.The main adverse events(AEs)were mild hypertension and proteinuria,which could be controlled.CONCLUSION Apatinib has clear efficacy and good tolerance in patients with multiple brain micrometastases after failure of second-line treatment.

关 键 词：Esophageal SQUAMOUS cell carcinoma Cervical ADENOCARCINOMA BRAIN MICROMETASTASES Apatinib TYROSINE kinase inhibitor Vascular endothelial growth factor 

分 类 号：R737.33[医药卫生—肿瘤] R735.1[医药卫生—临床医学]